PPMonitor checks laboratory air quality

Published: 12-Apr-2010
Design & Build HVAC Regulatory

Enables effective and flexible management of indoor air quality

PPM Technology’s wireless IAQ profile PPMonitor enables simple, effective and flexible management of the indoor air environment of a laboratory or cleanroom.

The PPMonitor, from the Caernarfon, Wales firm, can continuously detect, measure and record temperature, humidity, formaldehyde, nitrogen dioxide, carbon monoxide, carbon dioxide, sulphur dioxide, ozone, ammonia and TVOCs.

The device incorporates a variety of advanced gas sensor technologies to monitor the target gases including NDIR, PID and electrochemical sensors.

The wireless units communicate via the Zigbee wireless mesh network, which can be extended by adding repeater nodes or additional PPMonitor or Mini PPMonitor units. Each unit can be configured with unique sensor specifications if required, allowing complete monitoring of the cleanroom air environment.

PPMonitor Units can be wirelessly connected to a Building Management System, in which BMS software allows the entire wireless system to be managed from a single PC. The BMS can activate and control air conditioning and ventilation systems; it can also turn on/off heating and trigger building alarms, if required.

All recorded data is stored automatically with dedicated software, which enables the data to be viewed graphically and produces reports and statistical data. Analysis of the recorded data over time allows for more efficient management of resources and energy.

See more

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Read more
Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    From stockpiles to smart supply chains: how industry wants to fix Europe’s drug shortages An EU-level stockpile may work, but only if it’s flexible, closely monitored and built with logistics in mind. Industry players say drug security will depend less on volume and more on data, digital oversight and early collaboration throughout the supply chain
  2. European Commission approves Teva denosumab biosimilars PONLIMSI and DEGEVMA The two biosimilars to Prolia and Xgeva will expand access to important bone health treatments across Europe and bolster Teva's strong biosimilars portfolio
  3. Updated MHRA GMP certificates strengthen Piramal’s bioconjugates capabilities at Grangemouth Certification renewal supports clinical and commercial ADC development and manufacturing
  4. EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
  5. QInscribe unveils AI-powered medical writing to revolutionise regulatory submissions New medical writing service provider QInscribe reduces the time to generate a draft clinical study report (CSR) by 90% with a generative AI solution

Upcoming event

Pharmapack

21–22 January 2026 | Exhibition | Paris, France See all

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Regulatory

NOAH calls for Veterinary Medicines Agreement amid concerns over Northern Ireland veterinary medicines supply changes

With EU regulations set to apply fully from 1 January 2026, Northern Ireland could see 10-15% of veterinary medicines discontinued. Industry and government are working on mitigation schemes to protect animal health and ensure continued access to essential treatments
Regulatory

Piramal Pharma Solutions’ bioconjugates facility in Grangemouth, UK, receives updated MHRA GMP certificates

These certificates cover all activities conducted in the site’s Helix building, including its supporting warehouse and laboratory areas
Regulatory

UK-US pharma deal removes tariffs and boosts access to innovative medicines

The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Regulatory

European Commission approves Teva denosumab biosimilars PONLIMSI and DEGEVMA

The two biosimilars to Prolia and Xgeva will expand access to important bone health treatments across Europe and bolster Teva's strong biosimilars portfolio
Subscribe now